Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30692795 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22117617 | 0.92 | CHRNB2 (0.45) | CHRNB2CHRNA4 | |
| SCHEMBL20577124 | 0.84 | CHRNB2 (0.42) | CHRNB2CHRNA4HRH3 | |
| SCHEMBL30692819 | 0.84 | CHRNB2 (0.42) | CHRNB2CHRNA4HRH3 | |
| SCHEMBL1109106 | 0.84 | CYP2D6 (0.47) | CHRNB2CHRNA4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15901278 | 0.82 | CHRNB2 (0.41) | CHRNB2CHRNA4SMN1; SMN2 | |
| SCHEMBL15082431 | 0.82 | MAPT (0.44) | CHRNB2CHRNA4SMN1; SMN2 | |
| SCHEMBL16536086 | 0.82 | CHRNB2 (0.43) | CHRNB2CHRNA4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17658773 | 0.82 | CHRNB2 (0.43) | CHRNB2CHRNA4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15918593 | 0.81 | CHRNB2 (0.40) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230026909-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2023-01-26 | — | — | US | disclosed |
| US-20200339569-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2020-10-29 | — | — | US | disclosed |
| EP-3720851-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2020-10-14 | — | — | EP | disclosed |
| WO-2019110663-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2019-06-13 | — | — | WO | disclosed |
| WO-2018219478-A1 | HETEROARYL-CARBOXAMIDES AS HISTONE DEMETHYLASE INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2018-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339569-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITORS | HDAC6, HDAC1, HDAC3 | CHRNB2 3915/4885CHRNA4 3603/4885NPC1 1028/4885 |
| US-20230026909-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITORS | HDAC6, HDAC1, HDAC3 | CHRNB2 3915/4885CHRNA4 3603/4885NPC1 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.